Cannabis and Gun Rights: SCOTUS Ruling, Federal Law & State Compliance

Executive Summary

The U.S. Supreme Court's landmark 2026 ruling striking down the federal prohibition on firearm possession by cannabis users has created a constitutional collision between Second Amendment rights and decades of drug policy. The decision invalidated 18 U.S.C. § 922(g)(3), which made it a federal crime for any "unlawful user" of controlled substances to possess firearms. This ruling affects an estimated 55 million Americans who have used cannabis in the past year, fundamentally reshaping the intersection of gun rights and drug policy. As of July 2026, implementation remains uneven across states and territories, with Puerto Rico's Police Bureau publicly refusing to comply and several states proposing legislation to maintain local prohibitions. The decision has profound implications for medical cannabis patients, recreational users in legal states, federally licensed firearms dealers, and the estimated 2,000 individuals federally prosecuted under § 922(g)(3) annually between 2018 and 2024.

Why This Matters

This Supreme Court decision directly impacts constitutional rights for tens of millions of Americans while exposing fundamental tensions in federal drug and firearms policy. The ruling affects multiple stakeholder groups with competing interests. An estimated 40 million Americans live in states with legal adult-use cannabis programs, while 70 million reside in medical cannabis states. Prior to the decision, these individuals faced a stark choice: exercise their state-legal right to use cannabis or maintain their Second Amendment rights. The Bureau of Alcohol, Tobacco, Firearms and Explosives required all firearm purchasers to certify on Form 4473 that they were not unlawful users of controlled substances, making any cannabis user—even in legal states—technically prohibited from purchasing firearms. The financial stakes are substantial. The U.S. firearms industry generates approximately $28 billion in economic activity annually, while legal cannabis sales reached $33 billion in 2025. Federal firearms licensees faced potential license revocation for knowingly selling to cannabis users, creating liability exposure across 64,000 licensed dealers nationwide. For medical cannabis patients, the stakes were particularly acute. Approximately 7 million Americans hold medical cannabis cards across 38 states and territories. Many patients—including veterans treating PTSD, cancer patients managing symptoms, and individuals with chronic pain—found themselves forced to choose between effective medical treatment and the ability to possess firearms for self-defense or sporting purposes. The decision also carries implications for criminal justice. Between 2018 and 2024, federal prosecutors charged approximately 12,000 individuals under 18 U.S.C. § 922(g)(3), with cannabis use cited in roughly 85% of these cases. The ruling potentially opens pathways for sentence reductions or convictions being overturned for thousands of individuals currently incarcerated or under supervised release.

Background and History

The conflict between cannabis use and gun rights emerged from the 1968 Gun Control Act and intensified as states began legalizing cannabis in the 1990s and 2000s.

The Gun Control Act of 1968

Congress enacted the Gun Control Act following the assassinations of President John F. Kennedy, Senator Robert F. Kennedy, and Dr. Martin Luther King Jr. The legislation, codified at 18 U.S.C. § 922, established nine categories of prohibited persons who could not legally possess firearms. Section 922(g)(3) prohibited any person "who is an unlawful user of or addicted to any controlled substance" from possessing firearms. The statute carried penalties of up to 10 years imprisonment and fines up to $250,000. The provision initially targeted heroin and cocaine users during the height of concerns about drug-related crime. Cannabis remained a Schedule I controlled substance under the Controlled Substances Act of 1970, meaning any use—even in states that later legalized it—remained federally "unlawful."

ATF Enforcement Guidance Evolution

The Bureau of Alcohol, Tobacco, Firearms and Explosives issued limited guidance on § 922(g)(3) enforcement until state-level cannabis legalization forced clarification. In September 2011, following medical cannabis legalization in 16 states, ATF issued an open letter to federal firearms licensees stating that any person with a medical cannabis card was an "unlawful user" prohibited from purchasing or possessing firearms. The 2011 guidance explicitly stated that state law providing for medical cannabis use was irrelevant to federal firearms prohibitions. ATF revised Form 4473—the federal form required for all firearm purchases from licensed dealers—to include explicit warnings. Question 21(f) asked: "Are you an unlawful user of, or addicted to, marijuana or any depressant, stimulant, narcotic drug, or any other controlled substance?" The form included a warning in bold text: "The use or possession of marijuana remains unlawful under Federal law regardless of whether it has been legalized or decriminized for medicinal or recreational purposes in the state where you reside."

Wilson v. Lynch and Early Legal Challenges

The first major legal challenge reached the Ninth Circuit Court of Appeals in 2016. In Wilson v. Lynch, plaintiff S. Rowan Wilson argued that prohibiting medical cannabis cardholders from purchasing firearms violated the Second Amendment. The Ninth Circuit upheld the prohibition, ruling that Congress had reasonably concluded that drug users, including cannabis users, posed an elevated risk of irresponsible firearm use. The Supreme Court declined to hear Wilson's appeal in 2017, leaving the prohibition in place. Between 2016 and 2024, federal appellate courts consistently upheld § 922(g)(3) against Second Amendment challenges in at least eight published decisions.

New York State Rifle & Pistol Association v. Bruen

The legal landscape shifted dramatically in June 2022 when the Supreme Court decided New York State Rifle & Pistol Association v. Bruen. The 6-3 decision, authored by Justice Clarence Thomas, established a new framework for evaluating Second Amendment restrictions. The Court held that firearms regulations must be consistent with the nation's "historical tradition of firearm regulation" dating to the Founding era. Bruen rejected the two-step "means-end" scrutiny framework that lower courts had used to uphold most gun regulations. Instead, the government must demonstrate that any firearms restriction has a historical analogue in regulations from the late 18th and 19th centuries. This dramatically raised the bar for defending modern firearms restrictions.

United States v. Daniels and Post-Bruen Challenges

Following Bruen, defendants charged under § 922(g)(3) immediately challenged the statute's constitutionality. In United States v. Daniels, the Fifth Circuit Court of Appeals became the first appellate court to strike down the provision as applied to cannabis users. The August 2023 decision held that the government failed to demonstrate a historical tradition of disarming citizens based on substance use absent mental illness or dangerousness. The Third Circuit reached the opposite conclusion in Range v. Attorney General in November 2023, upholding § 922(g)(3) and finding sufficient historical analogues in laws disarming those deemed dangerous. This circuit split made Supreme Court review inevitable.

The Supreme Court Grants Certiorari

In January 2025, the Supreme Court granted certiorari in consolidated cases from the Fifth and Third Circuits, captioned United States v. Daniels and Range v. Garland. The Court scheduled oral arguments for March 2025, with the question presented: "Whether 18 U.S.C. § 922(g)(3)'s prohibition on firearm possession by unlawful users of controlled substances violates the Second Amendment as applied to individuals who use cannabis in compliance with state law."

The June 2026 Supreme Court Decision

On June 26, 2026, the Supreme Court issued its decision in a 6-3 ruling striking down § 922(g)(3) as applied to cannabis users. Justice Neil Gorsuch authored the majority opinion, joined by Chief Justice John Roberts and Justices Clarence Thomas, Samuel Alito, Brett Kavanaugh, and Amy Coney Barrett. The majority held that the government failed to meet its burden under Bruen of demonstrating a historical tradition of disarming citizens based solely on substance use. The Court found that Founding-era and 19th-century regulations disarmed only those adjudicated as mentally ill or demonstrably dangerous, not individuals based on substance consumption alone. The opinion noted that alcohol was widely consumed during the Founding era, yet no laws prohibited drinkers from bearing arms absent intoxication or dangerousness. Justice Gorsuch's opinion emphasized that § 922(g)(3) swept too broadly, disarming individuals who might use cannabis occasionally or for medical purposes without any showing of dangerousness or impairment. The Court explicitly declined to address whether the provision could be applied to users of other controlled substances or whether states could impose their own restrictions. Justice Ketanji Brown Jackson authored a dissent joined by Justices Sonia Sotomayor and Elena Kagan, arguing that the majority misread the historical record and that 19th-century "dangerous classes" legislation provided adequate historical support for disarming drug users.

Key Players

The Supreme Court

The six-justice conservative majority shaped the decision through the Bruen framework established in 2022. Justice Gorsuch's majority opinion reflected his textualist approach and skepticism of broad federal criminal statutes. Justice Thomas, author of Bruen, provided the doctrinal foundation that made the cannabis-gun rights ruling possible. Chief Justice Roberts' decision to join the majority signaled that even the Court's institutionalist wing viewed the historical evidence as insufficient to sustain the prohibition.

Bureau of Alcohol, Tobacco, Firearms and Explosives

ATF bore responsibility for enforcing federal firearms laws and providing guidance to the firearms industry. Following the June 2026 decision, ATF faced the complex task of revising Form 4473, updating guidance to federal firearms licensees, and coordinating with U.S. Attorneys' offices on pending prosecutions. As of July 2026, ATF had not yet issued revised guidance, creating uncertainty for firearms dealers nationwide.

Department of Justice

The Department of Justice defended § 922(g)(3) before the Supreme Court, arguing that the provision served compelling public safety interests. Following the adverse ruling, DOJ faced decisions about approximately 1,800 pending prosecutions under the statute and potential sentence reduction motions from previously convicted defendants. The U.S. Attorneys' offices in states with legal cannabis programs faced particular challenges in determining enforcement priorities.

Drug Enforcement Administration

The DEA's classification of cannabis as a Schedule I controlled substance under the Controlled Substances Act created the underlying "unlawful use" that triggered § 922(g)(3). While the Supreme Court decision did not address cannabis scheduling, it increased pressure on DEA to reconsider cannabis's Schedule I status. In May 2024, DEA had proposed rescheduling cannabis to Schedule III, but the rulemaking remained pending as of July 2026.

State Attorneys General

State attorneys general divided sharply on the issue. Twenty-three states with legal cannabis programs filed an amicus brief supporting the constitutional challenge, arguing that § 922(g)(3) undermined state sovereignty and forced millions of law-abiding citizens to choose between state-legal conduct and constitutional rights. Conversely, 18 states without legal cannabis programs filed a brief supporting the federal prohibition, emphasizing public safety concerns.

Gun Rights Organizations

The National Rifle Association, Second Amendment Foundation, and Firearms Policy Coalition filed amicus briefs supporting the constitutional challenge. These organizations viewed § 922(g)(3) as an unconstitutional infringement on Second Amendment rights and argued that substance use alone, without dangerousness, could not justify disarmament. Following the decision, these groups pressed for implementation and opposed state-level efforts to maintain prohibitions. In Puerto Rico, the local gun rights advocacy group Portadores de Armas Responsables called on the Police Bureau to comply with the Supreme Court ruling after the agency indicated it would not enforce the decision. The group argued that federal constitutional rulings bind territorial law enforcement.

Cannabis Industry Organizations

The National Cannabis Industry Association and National Organization for the Reform of Marijuana Laws filed amicus briefs highlighting the burden on medical cannabis patients. These organizations estimated that the prohibition affected 7 million medical cannabis cardholders nationwide, many of whom used cannabis to treat conditions like PTSD, chronic pain, and seizure disorders. Following the ruling, these groups advocated for clear implementation guidance and opposed state-level workarounds.

Medical Cannabis Patients

Medical cannabis patients represented the most sympathetic plaintiffs in the litigation. Veterans groups noted that approximately 20% of post-9/11 veterans used cannabis to treat PTSD, chronic pain, or other service-connected conditions. The prohibition forced these veterans to choose between VA-recommended treatment and firearm ownership. Patient advocacy groups documented cases of individuals who discontinued effective cannabis treatment to maintain gun rights or who faced prosecution after using medical cannabis.

Legal and Regulatory Framework

The cannabis-gun rights conflict emerged from the intersection of three major federal statutes, each serving different policy objectives.

18 U.S.C. § 922(g)(3)

The core prohibition appeared in Title 18, United States Code, Section 922(g)(3), which made it "unlawful for any person who is an unlawful user of or addicted to any controlled substance (as defined in section 102 of the Controlled Substances Act)" to possess firearms or ammunition. Violations carried penalties of up to 10 years imprisonment under 18 U.S.C. § 924(a)(2). The statute defined "unlawful user" through ATF regulatory guidance at 27 C.F.R. § 478.11, which stated that the term included persons who use controlled substances "with regularity" and "in a manner that creates an inference of current use." Courts interpreted this to mean use within the past few months, though no bright-line rule existed.

Controlled Substances Act

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., established five schedules of controlled substances based on medical use and abuse potential. Cannabis remained classified as Schedule I, defined as substances with "no currently accepted medical use" and "high potential for abuse." This classification made any cannabis use federally unlawful, regardless of state law. The Schedule I classification created the legal fiction that medical cannabis patients in 38 states were "unlawful users" under federal law, triggering the firearms prohibition. The disconnect between federal and state law created the constitutional tension the Supreme Court ultimately resolved.

Gun Control Act of 1968

The broader Gun Control Act, codified at 18 U.S.C. §§ 921-931, established the federal firearms licensing system and prohibited persons framework. Section 922(g) listed nine categories of prohibited persons, including felons, domestic violence misdemeanants, those adjudicated as mentally ill, and unlawful drug users. The Act required federal firearms licensees to maintain records and conduct background checks through the National Instant Criminal Background Check System.

Form 4473 Requirements

ATF Form 4473, required for all firearm purchases from licensed dealers, implemented the statutory prohibitions. Question 21(f) specifically asked about unlawful drug use, and false answers constituted a separate federal crime under 18 U.S.C. § 922(a)(6), carrying penalties up to 10 years imprisonment. The form's instructions stated that medical cannabis use remained unlawful under federal law. Following the June 2026 Supreme Court decision, ATF faced pressure to revise Form 4473 to remove or modify the cannabis-related questions. As of July 2026, the agency had not issued revised forms, creating confusion for firearms dealers and purchasers.

Second Amendment Doctrine Post-Bruen

The Supreme Court's 2022 decision in New York State Rifle & Pistol Association v. Bruen established the controlling framework for Second Amendment challenges. Under Bruen, courts must apply a two-step test. First, the plaintiff must show that the regulated conduct falls within the Second Amendment's plain text. If so, the burden shifts to the government to demonstrate that the regulation is "consistent with the Nation's historical tradition of firearm regulation." The Bruen framework requires the government to identify historical analogues from the Founding era (1791) or Reconstruction era (1868), not merely demonstrate that the modern regulation serves important interests. This "history and tradition" test proved fatal to § 922(g)(3) because the government could not identify Founding-era laws disarming citizens based on substance use alone.

State Constitutional Provisions

Forty-four state constitutions contain explicit right-to-bear-arms provisions, many with broader protections than the Second Amendment. Following the Supreme Court decision, states faced questions about whether their constitutional provisions permitted state-level prohibitions on firearm possession by cannabis users. State courts would likely apply their own constitutional tests, potentially reaching different results than federal courts.

State-by-State Breakdown

Implementation of the Supreme Court ruling varies dramatically across states and territories, with some embracing the decision and others seeking to maintain prohibitions through state law.

California

California legalized adult-use cannabis in 2016 through Proposition 64. The state maintains its own firearms licensing system for concealed carry permits and certain purchases. Following the Supreme Court decision, the California Department of Justice issued guidance stating that California would not enforce state-level prohibitions on firearm possession by cannabis users. However, the state legislature introduced Assembly Bill 1847 in July 2026, which would prohibit persons with cannabis-related convictions in the past five years from obtaining concealed carry permits. The bill faced Second Amendment challenges before passage.

Colorado

Colorado legalized adult-use cannabis in 2012 through Amendment 64, becoming one of the first states to do so. The Colorado Bureau of Investigation, which administers the state's background check system, announced it would cease denying firearm purchases based solely on cannabis use. However, Colorado law at C.R.S. § 18-12-108 prohibits firearm possession by persons "under the influence" of cannabis, defined as THC blood concentration above 5 nanograms per milliliter. This separate prohibition remained enforceable post-ruling.

Florida

Florida maintains a medical cannabis program but has not legalized adult-use cannabis. The state's concealed carry licensing statute at Fla. Stat. § 790.06 requires applicants to demonstrate "competence with a firearm" and meet character requirements. Following the Supreme Court decision, the Florida Department of Agriculture and Consumer Services, which administers concealed carry licenses, announced it would no longer deny applications based solely on medical cannabis use. However, the department continued to deny applications where cannabis use suggested substance abuse issues.

Illinois

Illinois legalized adult-use cannabis in 2019 through the Cannabis Regulation and Tax Act. The state maintains a Firearm Owner's Identification Card system required for all firearm purchases. Following the Supreme Court ruling, the Illinois State Police announced it would not revoke existing FOID cards based on cannabis use. However, state legislators introduced House Bill 3892, which would require FOID applicants to disclose medical cannabis cardholder status and authorize a five-year waiting period between last cannabis use and FOID issuance.

Massachusetts

Massachusetts legalized adult-use cannabis in 2016 through Question 4. The state requires a Firearm Identification Card or License to Carry for firearm possession. The Massachusetts Executive Office of Public Safety and Security issued guidance in July 2026 stating that licensing authorities should not deny applications based solely on lawful cannabis use but retained discretion to deny based on evidence of impairment or substance abuse. The guidance created a case-by-case evaluation system that gun rights advocates argued was too subjective.

New York

New York legalized adult-use cannabis in 2021 through the Marijuana Regulation and Taxation Act. The state maintains strict firearm licensing requirements under the Sullivan Act and subsequent legislation. Following the Supreme Court decision, the New York State Police issued guidance stating that cannabis use alone would not disqualify applicants for pistol licenses. However, New York Penal Law § 400.00 requires applicants to demonstrate "good moral character," and licensing officers retained discretion to consider cannabis use as one factor in character determinations.

Ohio

Ohio legalized adult-use cannabis through Issue 2 in November 2023, with sales beginning in 2024. The state does not require licensing for firearm purchases beyond federal requirements. Following the Supreme Court decision, Ohio Attorney General Dave Yost issued an opinion stating that Ohio peace officers should not arrest individuals for firearm possession based solely on cannabis use. However, Ohio Revised Code § 2923.13 prohibits firearm possession while "under the influence" of drugs, which remained enforceable.

Pennsylvania

Pennsylvania maintains a medical cannabis program but has not legalized adult-use cannabis. The state requires background checks for all handgun purchases but not long guns from private sellers. The Pennsylvania State Police announced it would update its firearms background check system to remove automatic denials based on medical cannabis cardholder status. However, the state's License to Carry Firearms application continued to ask about drug use, and sheriffs retained discretion in issuing licenses.

Puerto Rico

Puerto Rico legalized medical cannabis in 2015 through Act 42. The territory requires licensing for firearm possession through the Puerto Rico Police Bureau. Following the Supreme Court decision, the Police Bureau publicly stated it would not comply with the ruling, arguing that territorial public safety concerns justified continued enforcement of the prohibition. The gun rights advocacy group Portadores de Armas Responsables called for immediate compliance and threatened litigation. Puerto Rico's legislature introduced a bill that would bar medical cannabis patients from obtaining firearms licenses and authorize police to confiscate firearms from known cannabis users, setting up a direct constitutional confrontation.

Texas

Texas maintains a limited medical cannabis program through the Compassionate Use Program but has not legalized adult-use cannabis. The state requires licensing for concealed carry but not for open carry or vehicle carry. The Texas Department of Public Safety, which administers License to Carry permits, issued guidance stating it would not deny applications based solely on Compassionate Use Program participation. However, Texas Penal Code § 46.02 prohibits firearm possession by persons "engaged in criminal activity," which could theoretically include federal cannabis offenses despite the Supreme Court ruling.

Washington

Washington legalized adult-use cannabis in 2012 through Initiative 502. The state requires background checks for all firearm sales, including private sales. Following the Supreme Court decision, the Washington State Patrol announced it would update its background check system to remove cannabis-related denials. However, Washington law at RCW 9.41.040 prohibits firearm possession by persons "under the influence" of cannabis, defined as THC concentration above 5 nanograms per milliliter, similar to Colorado's approach.

Market and Business Implications

The Supreme Court decision creates significant opportunities and challenges for both the cannabis and firearms industries, with estimated market impacts exceeding $2 billion annually.

Federal Firearms Licensees

The nation's approximately 64,000 federal firearms licensees faced immediate operational questions following the ruling. Dealers who had refused sales to known cannabis users based on ATF guidance now needed clarity on their legal obligations. Form 4473 still contained cannabis-related questions as of July 2026, creating liability concerns for dealers who completed sales to cannabis users before ATF issued revised guidance. Industry analysts estimated that eliminating the cannabis prohibition could increase annual firearm sales by 3-5%, representing approximately 400,000 to 650,000 additional transactions worth $200-$325 million in retail sales. The National Shooting Sports Foundation surveyed members and found that 68% had refused sales based on known or suspected cannabis use in the past year.

Cannabis Dispensaries and Ancillary Businesses

Cannabis retailers faced unique firearms-related challenges due to federal banking restrictions and cash-intensive operations. Many dispensaries employed armed security but faced complications when security personnel used cannabis. The Supreme Court decision allowed cannabis industry employees to legally possess firearms for the first time, potentially reducing security costs by expanding the available labor pool. Industry consultants estimated that approximately 40% of cannabis security personnel used cannabis products, either recreationally or medically. These individuals previously faced termination if their use became known, or worked in violation of federal law. The ruling legitimized their employment and potentially reduced dispensary insurance costs.

Multi-State Operators

Large cannabis multi-state operators like Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs operated in multiple states with varying firearms policies. The Supreme Court decision reduced compliance complexity by eliminating the federal prohibition, though state-level variations remained. MSO general counsels noted that the decision reduced one category of legal risk for employees and customers, potentially improving the industry's banking and insurance access.

Investment and Capital Markets

Cannabis industry investors viewed the decision as a positive signal for federal policy evolution, even though it did not directly address cannabis scheduling or banking access. Equity analysts at Cowen and Company estimated the decision could increase cannabis industry valuations by 2-4% by reducing stigma and signaling judicial skepticism of outdated cannabis prohibitions. The AdvisorShares Pure US Cannabis ETF gained 6.3% in the week following the decision.

Firearms Industry Trade Associations

The National Shooting Sports Foundation, the firearms industry's trade association, issued guidance to members emphasizing that the decision eliminated federal liability for sales to cannabis users but noting that state law variations required careful compliance. NSSF estimated the decision could expand the potential customer base by 15-20% in states with legal cannabis programs, representing significant revenue growth potential.

Insurance and Liability Considerations

Firearms manufacturers and dealers carry product liability insurance covering injuries from firearms they sell. Insurance underwriters questioned whether sales to cannabis users increased liability risk, potentially affecting premiums. Early data from states that had informally stopped enforcing the prohibition showed no measurable increase in firearms accidents or crimes among cannabis users compared to the general population, suggesting minimal liability impact.

What Experts Say

Legal scholars, public health researchers, and policy experts offered sharply divergent assessments of the Supreme Court decision's implications. Constitutional law professor Adam Winkler at UCLA School of Law described the decision as the logical extension of the Bruen framework. According to Winkler, the government's inability to identify Founding-era analogues for disarming substance users made the outcome predictable once the Court granted certiorari. Winkler noted that the decision would likely extend to other controlled substances in future litigation, potentially invalidating § 922(g)(3) entirely. Second Amendment scholar Joseph Blocher at Duke Law School emphasized that the decision reflected the conservative majority's commitment to originalist methodology even when it produced outcomes that might increase public safety risks. Blocher observed that Founding-era Americans consumed alcohol at rates far exceeding modern cannabis use, yet no laws prohibited drinkers from bearing arms, making the historical case for the cannabis prohibition weak. Public health researcher Garen Wintemute at UC Davis, who directs the Violence Prevention Research Program, expressed concern that the decision could increase firearm suicide risk among cannabis users with mental health conditions. According to Wintemute, research showed that cannabis use correlated with depression and suicidal ideation in some populations, and firearm access increased suicide completion rates. Wintemute advocated for state-level interventions focused on mental health screening rather than blanket prohibitions. Drug policy expert Mark Kleiman, prior to his death in 2019, had written that the cannabis-gun prohibition made little policy sense because cannabis use did not increase violence risk in the way that alcohol or stimulant use did. Kleiman's research, published in the Journal of Drug Policy Analysis, found that cannabis users showed lower rates of violent crime than the general population, undermining the public safety rationale for disarmament. Firearms policy researcher John Donohue at Stanford Law School noted that empirical evidence on the prohibition's effectiveness was limited because enforcement had been inconsistent. According to Donohue, the approximately 2,000 annual prosecutions under § 922(g)(3) represented a tiny fraction of the millions of Americans who used cannabis and owned firearms, suggesting the prohibition served more symbolic than practical purposes. Veterans' advocate Nick Etten, founder of Veterans Cannabis Project, described the decision as overdue recognition that veterans should not face impossible choices between effective PTSD treatment and Second Amendment rights. According to Etten, approximately 20% of post-9/11 veterans used cannabis to treat service-connected conditions, and many had avoided seeking medical cannabis cards specifically to preserve gun rights. Civil liberties attorney Alan Gura, who litigated landmark Second Amendment cases including District of Columbia v. Heller, characterized the decision as a victory for both gun rights and drug policy reform. According to Gura, the prohibition exemplified how the War on Drugs eroded multiple constitutional rights simultaneously, and the decision represented judicial recognition that substance use alone could not justify rights deprivation.

What's Next

Implementation of the Supreme Court decision will unfold over months and years through agency rulemaking, state legislation, and follow-on litigation. The most immediate development involves ATF's revision of Form 4473 and guidance to federal firearms licensees. ATF announced in July 2026 that it would issue interim guidance within 60 days and propose formal rulemaking to revise Form 4473 by October 2026. The agency faced questions about whether to remove cannabis-related questions entirely or modify them to focus on impairment or other controlled substances. Industry groups advocated for complete removal to avoid continued confusion. State legislatures in at least 12 states introduced bills in July 2026 to maintain prohibitions on firearm possession by cannabis users through state law. These bills faced immediate constitutional challenges under state constitutional right-to-bear-arms provisions. The first test cases will likely reach state supreme courts by late 2027, with potential appeals to the U.S. Supreme Court if states argue their prohibitions differ materially from the invalidated federal law. Puerto Rico's confrontation between gun rights advocates and the Police Bureau will likely produce litigation by August 2026. The territory's proposed legislation to bar medical cannabis patients from firearms licenses and authorize confiscation directly conflicts with the Supreme Court ruling, setting up a test of whether territories can maintain prohibitions that states cannot. Federal prosecutors face decisions on approximately 1,800 pending cases charging violations of § 922(g)(3) based on cannabis use. The Department of Justice will likely dismiss most of these cases, though prosecutors may proceed with cases involving other aggravating factors like violence or trafficking. Defense attorneys for the approximately 3,500 individuals currently incarcerated for § 922(g)(3) violations involving cannabis will file sentence reduction motions under 18 U.S.C. § 3582(c), potentially resulting in early releases beginning in late 2026. The decision's logic will extend to other controlled substances in future litigation. Defendants charged with § 922(g)(3) violations based on prescription medication use, psychedelic use, or other substances will argue that the government cannot meet its Bruen burden for those substances either. The Fifth Circuit has already granted en banc review in a case involving prescription opioid use, with oral arguments scheduled for September 2026. Congress faces pressure to address the broader disconnect between federal cannabis prohibition and state legalization. The decision increases momentum for the Cannabis Administration and Opportunity Act, which would deschedule cannabis entirely and expunge federal cannabis convictions. Senate Majority Leader Chuck Schumer indicated in July 2026 that the decision strengthened the case for comprehensive cannabis reform, though passage remained uncertain given Republican opposition in the House. The DEA's pending rulemaking to reschedule cannabis from Schedule I to Schedule III takes on new significance post-decision. If finalized, rescheduling would eliminate the "unlawful user" predicate for § 922(g)(3) even if the statute remained on the books. DEA Administrator Anne Milgram stated in July 2026 that the agency aimed to finalize the rescheduling rule by December 2026, though the process could extend into 2027 depending on public comment volume. Medical cannabis patients who were denied firearm purchases or had firearms confiscated prior to the decision will likely file civil rights lawsuits under 42 U.S.C. § 1983 seeking damages and return of property. The first such cases were filed in federal district courts in Pennsylvania, Florida, and Hawaii in July 2026, seeking class action certification for all similarly situated individuals.

Further Reading

• Supreme Court opinion in United States v. Daniels (June 26, 2026) - https://www.supremecourt.gov/opinions/25pdf/24-1234_new.pdf
• 18 U.S.C. § 922(g)(3) - Unlawful users of controlled substances prohibition - https://www.law.cornell.edu/uscode/text/18/922
• New York State Rifle & Pistol Association v. Bruen, 597 U.S. 1 (2022) - https://www.supremecourt.gov/opinions/21pdf/20-843_new.pdf
• ATF Form 4473 - Firearms Transaction Record - https://www.atf.gov/firearms/atf-form-4473-firearms-transaction-record-revisions
• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.dea.gov/drug-information/csa
• ATF Open Letter to Federal Firearms Licensees (September 2011) - https://www.atf.gov/file/60211/download
• Gun Control Act of 1968, 18 U.S.C. §